Relmada Therapeutics (RLMD) Other Accumulated Expenses (2019 - 2026)
Relmada Therapeutics (RLMD) posted quarterly Other Accumulated Expenses of $76100.0 for Q1 2026, up 12.57% year-over-year from $67600.0 in Q1 2025, and down 43.38% quarter-over-quarter from $134400.0 in Q4 2025.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Other Accumulated Expenses for 6 consecutive years, with $76100.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 12.57% year-over-year to $76100.0; the TTM figure through Mar 2026 stood at $76100.0 (up 12.57% YoY), while the FY2025 annual figure was $134400.0, up 3.86% from the prior year.
- Other Accumulated Expenses slipped to $76100.0 in Q1 2026 per RLMD's latest filing, from $134400.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $134400.0 in Q4 2025 and bottomed at $67600.0 in Q1 2025.
- Historically, Other Accumulated Expenses has averaged $95450.0 across 4 years, with a median of $80600.0 in 2024.
- Annual changes were most pronounced in 2025 — Other Accumulated Expenses increased 0.75% — and 2026, when it climbed 12.57%.
- Relmada Therapeutics' Other Accumulated Expenses stood at $115500.0 in 2023, then gained by 12.03% to $129400.0 in 2024, then grew by 3.86% to $134400.0 in 2025, then tumbled by 43.38% to $76100.0 in 2026.
- Business Quant data shows RLMD's Other Accumulated Expenses at $76100.0 in Q1 2026, $134400.0 in Q4 2025, and $80900.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 76,100.00 |
| Dec 31, 2025 | 134,400.00 |
| Sep 30, 2025 | 80,900.00 |
| Jun 30, 2025 | 79,400.00 |
| Mar 31, 2025 | 67,600.00 |
| Dec 31, 2024 | 129,400.00 |
| Sep 30, 2024 | 80,300.00 |
| Dec 31, 2023 | 115,500.00 |
| Dec 31, 2020 | 126,200.00 |
| Jun 30, 2020 | 65,900.00 |
| Dec 31, 2019 | 92,900.00 |
| Sep 30, 2019 | 65,200.00 |
| Jun 30, 2019 | 59,400.00 |